Business Context and Reporting Period
This Form 8-K is filed by Oncobiologics, Inc. (noted as Outlook Therapeutics, Inc. in metadata) on February 13, 2018. The report covers two primary events: the announcement of financial results for the first fiscal quarter ended December 31, 2017, and a regulatory decision regarding the company's stock listing status on The Nasdaq Stock Market.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the quarter ended December 31, 2017. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the information in the press release is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.
Material Changes and Listing Status
The most significant material change reported is the transfer of the company's listing from The Nasdaq Global Market to The Nasdaq Capital Market. This decision by the Nasdaq Hearings Panel was granted on February 13, 2018, following the company's failure to meet the $50 million market value of listed securities requirement for the Global Market. The company was granted an extension through May 15, 2018, to demonstrate compliance with the $35 million market value requirement for the Capital Market.
Outlook, Risks, and Contingencies
The primary risk identified is the company's continued non-compliance with Nasdaq listing standards regarding market value. The company faces a deadline of May 15, 2018, to evidence full compliance with the $35 million market value requirement to maintain its listing on The Nasdaq Capital Market. Failure to meet this requirement could result in delisting.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 14, 2018) for specific Q4 2017 financial figures, as they are not included in this 8-K text.
- Verify the company's current market capitalization to assess compliance with the $35 million Nasdaq Capital Market requirement.
- Monitor the May 15, 2018 deadline for the company to demonstrate compliance with Nasdaq listing standards.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.